SHP Wealth Management’s Alto Neuroscience ANRO Stock Holding History

SHP Wealth Management’s Portfolio ANRO Stock Details ANRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-25	Closed	-$562	–	2092
2026 Q1	$562	Hold	25	–	–	﹤0.01%	1601
2025 Q4	$445	Buy	+25	New	+$315	﹤0.01%	1384

Other funds holding ANRO

Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Spruce Street Capital New York $510M AUM

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

SHP Wealth Management's ANRO Position: Q2 2026 in Review

SHP Wealth Management sold out of Alto Neuroscience (ANRO) in Q2 2026, closing a stake of 25 shares — an estimated $562 sold.

SHP Wealth Management first reported a position in ANRO in Q4 2025 and held it in 2 quarters. The position peaked at $562 in Q1 2026. 114 funds tracked by Wall St. Rank hold ANRO as of Q2 2026.

SHP Wealth Management reported no remaining Alto Neuroscience position as of Q2 2026 after selling out during the quarter.
SHP Wealth Management sold 25 Alto Neuroscience shares in Q2 2026, an estimated $562.
SHP Wealth Management first reported a position in Alto Neuroscience in Q4 2025 and held it in 2 quarters.
SHP Wealth Management's Alto Neuroscience position peaked at $562 in Q1 2026.
114 funds tracked by Wall St. Rank held Alto Neuroscience as of Q2 2026.

Based on SHP Wealth Management's 13F filing for Q2 2026, filed 11 Aug 2026.